WILMINGTON, MA--(Marketwire - February 04, 2009) - DUSA Pharmaceuticals, Inc.® (NASDAQ: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 11th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf Astoria Hotel in New York on February 9-10, 2009. Mr. Doman is scheduled to present at 9:00 a.m. ET on February 9, 2009. Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website approximately one hour following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical
company focused primarily on the development and marketing of its
Levulan® photodynamic therapy (PDT) technology platform, and
complementary dermatology products. Levulan PDT is currently approved for
the treatment of Grade 1 or 2 actinic keratoses of the face or scalp. DUSA
is also researching additional indications for Levulan PDT, including oral
leukoplakia in collaboration with the National Institutes of Health (NIH)
and the prevention of AK's and SCC's in immunosuppressed solid organ
transplant recipients. DUSA is based in Wilmington, Massachusetts. Please
visit the company's Web site at www.dusapharma.com for more information.
